Funder
Division of Chemical, Bioengineering, Environmental, and Transport Systems
Discretionary Funds through Brown University
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,Modeling and Simulation
Reference64 articles.
1. Abdelnabi, M., A. Ahmed, A. Almaghraby, Y. Saleh, and H. Badran. Ivabradine and AF: coincidence, correlation or a new treatment? Arrhythm Electrophysiol. Rev. 8:300–303, 2020.
2. Amos, G. J., E. Wettwer, F. Metzger, Q. Li, H. M. Himmel, and U. Ravens. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J. Physiol. 491(Pt 1):31–50, 1996.
3. Benzoni, P., G. Campostrini, S. Landi, V. Bertini, E. Marchina, M. Iascone, G. Ahlberg, M. S. Olesen, E. Crescini, C. Mora, G. Bisleri, C. Muneretto, R. Ronca, M. Presta, P. L. Poliani, G. Piovani, R. Verardi, E. Di Pasquale, A. Consiglio, A. Raya, E. Torre, A. M. Lodrini, R. Milanesi, M. Rocchetti, M. Baruscotti, D. DiFrancesco, M. Memo, A. Barbuti, and P. Dell’Era. Human iPSC modelling of a familial form of atrial fibrillation reveals a gain of function of If and ICaL in patient-derived cardiomyocytes. Cardiovasc. Res. 116:1147–1160, 2020.
4. Branco, M. A., J. P. Cotovio, C. A. V. Rodrigues, S. H. Vaz, T. G. Fernandes, L. M. Moreira, J. M. S. Cabral, and M. M. Diogo. Transcriptomic analysis of 3D cardiac differentiation of human induced pluripotent stem cells reveals faster cardiomyocyte maturation compared to 2D culture. Sci. Rep. 9:9229, 2019.
5. Burashnikov, A., and C. Antzelevitch. How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation? J. Atr. Fibrillation. 1:98–107, 2008.